|
|
|
|
||
Re: ASCO2020 Late-Breaking Abstract LBA3- KRd not statistically significantly better than VRd for PFS in NDMM (for BMY heads or tails, still Rd backbone; for AMGN 2nd gen-PI not better than Velcade) And I understand velcade will be off patent in 2 years! So VRd will be cheaper soon. |
return to message board, top of board |